Lucid Diagnostics Inc. (LUCD)
After hours:
| Previous Close | 1.4800 |
| Open | 1.4700 |
| Bid | 1.4400 x 1300 |
| Ask | 1.4700 x 1000 |
| Day's Range | 1.4400 - 1.4800 |
| 52 Week Range | 1.0400 - 2.0000 |
| Volume | |
| Avg. Volume | 42,592 |
| Market Cap | 63.033M |
| Beta (5Y Monthly) | 1.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.4100 |
| Earnings Date | Nov 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.16 |
Insider MonkeyPAVmed Inc. (NASDAQ:PAVM) Q3 2023 Earnings Call Transcript
PAVmed Inc. (NASDAQ:PAVM) Q3 2023 Earnings Call Transcript November 15, 2023 Operator: Good day, and welcome to the PAVmed Third Quarter 2023 Business Update Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s remarks, there will be an opportunity to ask questions. [Operator Instructions] Please also note that today’s event […]
Insider MonkeyLucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2023 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good morning, and welcome to the Lucid Diagnostics Third Quarter 2023 Business Update Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please note that this event is being recorded. I would now like to turn the conference over […]
PR NewswireLucid Diagnostics Strengthens and Expands Market Access and Direct Contracting Efforts
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), announced that the Company has strengthened and expanded its executive team with two industry veterans to support its critical market access and direct contracting efforts. Natalie S. Carfora joins Lucid as Vice President, Market Access, and James M. Fricchione as Vice President, Employe
